Special Drug Use Surveillance of Entresto Tablets (Hypertension)

CompletedOBSERVATIONAL
Enrollment

1,125

Participants

Timeline

Start Date

September 4, 2023

Primary Completion Date

May 29, 2025

Study Completion Date

May 29, 2025

Conditions
Hypertension
Interventions
DRUG

Entresto

There is no treatment allocation. Patients administered Entresto by prescription that have started before inclusion of the patient into the study will be enrolled.

Trial Locations (117)

1940013

Novartis Investigative Site, Machida

2260025

Novartis Investigative Site, Yokohama

2270046

Novartis Investigative Site, Yokohama

3300074

Novartis Investigative Site, Saitama

3510021

Novartis Investigative Site, Asaka

444-1154

Novartis Investigative Site, Anjo

494-0001

Novartis Investigative Site, Ichinomiya

487-0024

Novartis Investigative Site, Kasugai

460-0004

Novartis Investigative Site, Nagoya

444-0856

Novartis Investigative Site, Okazaki

474-0044

Novartis Investigative Site, Ōbu

440-0836

Novartis Investigative Site, Toyohashi

498-0048

Novartis Investigative Site, Yatomi

270-1334

Novartis Investigative Site, Inzai

270-0034

Novartis Investigative Site, Matsudo

285-8765

Novartis Investigative Site, Sakura

284-0027

Novartis Investigative Site, Yotsukaidō

790-0051

Novartis Investigative Site, Matsuyama

790-0932

Novartis Investigative Site, Matsuyama

799-1371

Novartis Investigative Site, Saijō

815-0033

Novartis Investigative Site, Fukuoka

815-0041

Novartis Investigative Site, Fukuoka

816-0807

Novartis Investigative Site, Kasuga

816-0833

Novartis Investigative Site, Kasuga

811-2202

Novartis Investigative Site, Kasuya Gun

804-0081

Novartis Investigative Site, Kitakyushu

805-0019

Novartis Investigative Site, Kitakyushu

830-0011

Novartis Investigative Site, Kurume

811-1244

Novartis Investigative Site, Nakagawa

837-0916

Novartis Investigative Site, Omuta

834-0004

Novartis Investigative Site, Yame

731-0102

Novartis Investigative Site, Hiroshima

731-0154

Novartis Investigative Site, Hiroshima

731-0221

Novartis Investigative Site, Hiroshima

725-0026

Novartis Investigative Site, Takehara

001-0017

Novartis Investigative Site, Sapporo

060-0031

Novartis Investigative Site, Sapporo

064-0802

Novartis Investigative Site, Sapporo

064-0809

Novartis Investigative Site, Sapporo

673-0023

Novartis Investigative Site, Akashi

660-0861

Novartis Investigative Site, Amagasaki

679-0103

Novartis Investigative Site, Kasai

650-0047

Novartis Investigative Site, Kobe

651-1302

Novartis Investigative Site, Kobe

651-1505

Novartis Investigative Site, Kobe

651-2135

Novartis Investigative Site, Kobe

654-0121

Novartis Investigative Site, Kobe

663-8107

Novartis Investigative Site, Nishinomiya

306-0631

Novartis Investigative Site, Bandō

309-1195

Novartis Investigative Site, Chikusei

306-0232

Novartis Investigative Site, Koga

302-0118

Novartis Investigative Site, Moriya

301-0005

Novartis Investigative Site, Ryūgasaki

920-0007

Novartis Investigative Site, Kanazawa

892-0862

Novartis Investigative Site, Kagoshima

243-0301

Novartis Investigative Site, Aiko-gun

252-0804

Novartis Investigative Site, Fujisawa

225-0013

Novartis Investigative Site, Yokohama

232-0052

Novartis Investigative Site, Yokohama

235-0045

Novartis Investigative Site, Yokohama

241-0821

Novartis Investigative Site, Yokohama

238-0007

Novartis Investigative Site, Yokosuka

862-0924

Novartis Investigative Site, Kumamoto

861-0382

Novartis Investigative Site, Yamaga

811-5135

Novartis Investigative Site, Iki

852-8055

Novartis Investigative Site, Nagasaki

852-8511

Novartis Investigative Site, Nagasaki

871-0152

Novartis Investigative Site, Nakatsu

870-0837

Novartis Investigative Site, Ōita

710-1101

Novartis Investigative Site, Kurashiki

713-8121

Novartis Investigative Site, Kurashiki

573-0058

Novartis Investigative Site, Hirakata

563-0047

Novartis Investigative Site, Ikeda

562-0046

Novartis Investigative Site, Minoo

570-0012

Novartis Investigative Site, Moriguchi

570-8507

Novartis Investigative Site, Moriguchi

533-0013

Novartis Investigative Site, Osaka

534-0024

Novartis Investigative Site, Osaka

565-0862

Novartis Investigative Site, Suita

565-0874

Novartis Investigative Site, Suita

569-1121

Novartis Investigative Site, Takatsuki

561-0881

Novartis Investigative Site, Toyonaka

849-1311

Novartis Investigative Site, Kashima

849-1203

Novartis Investigative Site, Kishima-gun

841-0061

Novartis Investigative Site, Tosu

843-0302

Novartis Investigative Site, Ureshino

356-0011

Novartis Investigative Site, Fujimino

361-0056

Novartis Investigative Site, Gyōda

333-0847

Novartis Investigative Site, Kawaguchi

352-0023

Novartis Investigative Site, Niiza

339-0033

Novartis Investigative Site, Saitama

340-0115

Novartis Investigative Site, Satte

350-1305

Novartis Investigative Site, Sayama

359-1106

Novartis Investigative Site, Tokorozawa

359-1141

Novartis Investigative Site, Tokorozawa

196-0015

Novartis Investigative Site, Akishima

134-0081

Novartis Investigative Site, Edogawa-ku

192-0918

Novartis Investigative Site, Hachiōji

125-0042

Novartis Investigative Site, Katsushika-ku

185-0011

Novartis Investigative Site, Kokubunji

135-0003

Novartis Investigative Site, Koto-ku

194-0021

Novartis Investigative Site, Machida

195-0074

Novartis Investigative Site, Machida

181-0013

Novartis Investigative Site, Mitaka

146-8531

Novartis Investigative Site, Ōta-ku

157-0066

Novartis Investigative Site, Setagaya-ku

151-0053

Novartis Investigative Site, Shibuya City

171-0014

Novartis Investigative Site, Toshima-ku

939-1104

Novartis Investigative Site, Takaoka

759-6301

Novartis Investigative Site, Shimonoseki

754-0002

Novartis Investigative Site, Yamaguchi

810-0044

Novartis Investigative Site, Fukuoka

810-0801

Novartis Investigative Site, Fukuoka

812-0025

Novartis Investigative Site, Fukuoka

812-0039

Novartis Investigative Site, Fukuoka

814-0163

Novartis Investigative Site, Fukuoka

338-0837

Novartis Investigative Site, Saitama

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY